Knee Surgery, Sports Traumatology, Arthroscopy

, Volume 25, Issue 6, pp 1884–1891 | Cite as

Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin

  • Ferda Kaleağasıoğlu
  • Ercan OlcayEmail author
  • Vakur Olgaç



Accumulating clinical evidence indicates the risk of tendinopathy and spontaneous and/or simultaneous tendon ruptures associated with statin use. This experimental study was designed to evaluate and compare the biomechanical and histopathological effects of the three most commonly prescribed statins (simvastatin, atorvastatin and rosuvastatin) on the Achilles tendon in rats.


Statins were administered by gavage to rats at daily doses of 20 and 40 mg/kg for 3 weeks. One week later, the Achilles tendons were dissected and their biomechanical properties, including ultimate tensile force, yield force and elastic modulus, were determined. The samples were stained with haematoxylin–eosin and examined under a light microscope. The biomechanical properties of the tibia were tested by three-point bending test. Bone mineral density (BMD) and the lengths of tibias were measured by computed tomography.


All the statins caused deterioration of the biomechanical parameters of the Achilles tendon. Histopathological analysis demonstrated foci of dystrophic calcification only in the statin-treated groups. However, the number and the total area of calcific deposits were similar between the statin groups. The biomechanical parameters of tibias were improved in all the statin groups. BMD in the statin-treated groups was not significantly different from the control group.


All the statins tested are associated with calcific tendinopathy risk of which full awareness is required during everyday medical practice. However, statin-associated improvement of bone biomechanical properties is a favourable feature which may add to their beneficial effects in atherosclerotic cardiovascular disease, especially in the elderly.


Simvastatin Atorvastatin Rosuvastatin Biomechanics Calcific tendinopathy Achilles tendon Bone density 



The funding support from Turkish Society of Orthopaedics and Traumatology (TOTBID) for this work is gratefully acknowledged.

Author contribution

This research project was designed and conducted by F. Kaleağasıoğlu and E. Olcay who also interpreted the data, drafted the paper and revised it critically. V. Olgac conducted and interpreted the pathological analysis.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.


  1. 1.
    Beri A, Dwamena FC, Dwamena BA (2009) Association between statin therapy and tendon rupture: a case-control study. J Cardiovasc Pharmacol 53:401–404CrossRefPubMedGoogle Scholar
  2. 2.
    Beri A, Khattri S (2008) Tendon rupture and statin therapy: is there a link? Comment on the article by Marie et al. Arthritis Rheum 59:1202CrossRefPubMedGoogle Scholar
  3. 3.
    Carmont MR, Highland AM, Blundell CM, Davies MB (2009) Simultaneous bilateral Achilles tendon ruptures associated with statin medication despite regular rock climbing exercise. Phys Ther Sport 10:150–152CrossRefPubMedGoogle Scholar
  4. 4.
    Celik EC, Ozbaydar M, Ofluoglu D, Demircay E (2012) Simultaneous and spontaneous bilateral quadriceps tendons rupture. Am J Phys Med Rehabil 91:631–634CrossRefPubMedGoogle Scholar
  5. 5.
    Chazerain P, Hayem G, Hamza S, Best C, Ziza JM (2001) Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 68:430–433CrossRefPubMedGoogle Scholar
  6. 6.
    Choudhry NKDS, Shrank WH, Polinski JM, Stark CE, Gupta R, Prabhakaran D, Brill G, Jha P (2014) Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. Health Aff (Millwood) 33:273–282CrossRefGoogle Scholar
  7. 7.
    Conforti ACC, Moretti U, Colcera S, Fumagalli G, Leone R (2007) Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf 2:47–63CrossRefPubMedGoogle Scholar
  8. 8.
    de Oliveira LP, Vieira CP, Da Ré Guerra F, de Almeida Mdos S, Pimentel ER (2013) Statins induce biochemical changes in the Achilles tendon after chronic treatment. Toxicology 311:162–168CrossRefPubMedGoogle Scholar
  9. 9.
    de Oliveira LP, Vieira CP, Guerra FD, Almeida MS, Pimentel ER (2015) Structural and biomechanical changes in the Achilles tendon after chronic treatment with statins. Food Chem Toxicol 77:50–57CrossRefPubMedGoogle Scholar
  10. 10.
    Dolkart O, Liron T, Chechik O, Somjen D, Brosh T, Maman E, Gabet Y (2014) Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study. Am J Sports Med 42:2869–2876CrossRefPubMedGoogle Scholar
  11. 11.
    Fernandez G, Spatz ES, Jablecki C, Phillips PS (2011) Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 78:393–403CrossRefPubMedGoogle Scholar
  12. 12.
    Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP (2014) What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 21:464–474CrossRefPubMedGoogle Scholar
  13. 13.
    García MJ, Reinoso RF, Sánchez-Navarro A, Prous JR (2003) Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25:457–481CrossRefPubMedGoogle Scholar
  14. 14.
    Hoffman KB, Kraus C, Dimbil M, Golomb BA (2012) A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 7:e42866CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ioannidis JP (2014) More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 311:463–464. doi: 10.1001/jama.2013.284657 CrossRefPubMedGoogle Scholar
  16. 16.
    Itagaki M, Takaguri A, Kano S, Kaneta S, Ichihara K, Satoh K (2009) Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci 109:94–101CrossRefPubMedGoogle Scholar
  17. 17.
    Kaleagasioglu F, Olcay E (2012) Fluoroquinolone-induced tendinopathy: etiology and preventive measures. Tohoku J Exp Med 226:251–258CrossRefPubMedGoogle Scholar
  18. 18.
    Kirchgesner T, Larbi A, Omoumi P, Malghem J, Zamali N, Manelfe J, Lecouvet F, Vande Berg B, Djebbar S, Dallaudière B (2014) Drug-induced tendinopathy: from physiology to clinical applications. Joint Bone Spine. doi: 10.1016/j.jbspin.2014.03.022 PubMedGoogle Scholar
  19. 19.
    Klopstock T (2008) Drug-induced myopathies. Curr Opin Neurol 21:590–595CrossRefPubMedGoogle Scholar
  20. 20.
    Liantonio A, Giannuzzi V, Cippone V, Camerino GM, Pierno S, Camerino DC (2007) Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system. J Pharmacol Exp Ther 321:626–634CrossRefPubMedGoogle Scholar
  21. 21.
    Lui PP (2013) Histopathological changes in tendinopathy–potential roles of BMPs? Rheumatology (Oxford) 52:2116–2126CrossRefGoogle Scholar
  22. 22.
    MacDonald JS, Halleck MM (2004) The toxicology of HMG-CoA reductase inhibitors: prediction of human risk. Toxicol Pathol 32:26–41CrossRefPubMedGoogle Scholar
  23. 23.
    Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S (2014) Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 12:51CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Marie I, Delafenêtre H, Massy N, Thuillez C, Noblet C, NotFP Centers (2008) Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990–2005 and review of the literature. Arthritis Rheum 59:367–372CrossRefPubMedGoogle Scholar
  25. 25.
    Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S (2001) Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 21:1636–1641CrossRefPubMedGoogle Scholar
  26. 26.
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620CrossRefPubMedGoogle Scholar
  27. 27.
    Movahed MR, Samsamsharaiat SA (2006) Reproducible tendinitis-like symptoms related to statin therapy. J Clin Rheumatol 12:320–321CrossRefPubMedGoogle Scholar
  28. 28.
    Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949CrossRefPubMedGoogle Scholar
  29. 29.
    Olcay E, Beytemur O, Kaleagasioglu F, Gulmez T, Mutlu Z, Olgac V (2011) Oral toxicity of pefloxacin, norfloxacin, ofloxacin and ciprofloxacin: comparison of biomechanical and histopathological effects on Achilles tendon in rats. J Toxicol Sci 36:339–345CrossRefPubMedGoogle Scholar
  30. 30.
    Oliva F, Via AG, Maffulli N (2012) Physiopathology of intratendinous calcific deposition. BMC Med 10:95CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pedersen T, Gaw A (2001) Statins–similarities and differences. Am J Manag Care 7:S132–S137PubMedGoogle Scholar
  32. 32.
    Pullatt RC, Gadarla MR, Karas RH, Alsheikh-Ali AA, Thompson PD (2007) Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol 100:152–153CrossRefPubMedGoogle Scholar
  33. 33.
    Rubin G, Haddad E, Ben-Haim T, Elmalach I, Rozen N (2011) Bilateral, simultaneous rupture of the quadriceps tendon associated with simvastatin. Isr Med Assoc J 13:185–186PubMedGoogle Scholar
  34. 34.
    Sakamoto K, Kimura J (2013) Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci 123:289–294CrossRefPubMedGoogle Scholar
  35. 35.
    Savvidou CMR (2012) Spontaneous distal biceps tendon ruptures: are they related to statin administration? Hand Surg 17:167–171CrossRefPubMedGoogle Scholar
  36. 36.
    Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117–125CrossRefPubMedGoogle Scholar
  37. 37.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey MCN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SCJ, Watson K, Wilson PW (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology/american heart association task force on practice guidelines. Circulation 129:S1–S45CrossRefPubMedGoogle Scholar
  38. 38.
    Tsartsalis AN, Dokos C, Kaiafa GD, Tsartsalis DN, Kattamis A, Hatzitolios AI, Savopoulos CG (2012) Statins, bone formation and osteoporosis: hope or hype? Hormones (Athens) 11:126–139CrossRefGoogle Scholar
  39. 39.
    Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC (2005) Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 33:246–257CrossRefPubMedGoogle Scholar
  40. 40.
    Young JS, Maffuli N (2007) Etiology and epidemiology of Achilles tendon problems. In: Maffuli N, Almekinders LC (eds) The Achilles tendon. Springer, London, pp 39–49Google Scholar

Copyright information

© European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA) 2015

Authors and Affiliations

  • Ferda Kaleağasıoğlu
    • 1
  • Ercan Olcay
    • 2
    • 3
    Email author
  • Vakur Olgaç
    • 4
  1. 1.Department of Pharmacology, Faculty of MedicineUniversity of YeditepeIstanbulTurkey
  2. 2.Department of Orthopaedic Surgery, Faculty of MedicineUniversity of KafkasKarsTurkey
  3. 3.Department of Orthopaedic SurgeryKanuni Sultan Suleyman Educational HospitalIstanbulTurkey
  4. 4.Department of Pathology, Institute of OncologyUniversity of IstanbulIstanbulTurkey

Personalised recommendations